The estimated Net Worth of Daniel M Junius is at least $46.5 Milion dollars as of 10 May 2023. Mr. Junius owns over 30,000 units of Idexx Laboratories stock worth over $45,716,745 and over the last 20 years he sold IDXX stock worth over $432,556. In addition, he makes $307,482 as Independent Director at Idexx Laboratories.
Daniel has made over 48 trades of the Idexx Laboratories stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of IDXX stock worth $46,800 on 10 May 2023.
The largest trade he's ever made was exercising 46,667 units of Idexx Laboratories stock on 13 February 2018 worth over $154,001. On average, Daniel trades about 4,859 units every 46 days since 2005. As of 10 May 2023 he still owns at least 93,250 units of Idexx Laboratories stock.
You can see the complete history of Mr. Junius stock trades at the bottom of the page.
Daniel M. Junius serves as Independent Director of the Company. Mr. Junius was President and Chief Executive Officer of ImmunoGen, Inc. from 2009 until his retirement in May 2016. Before that, he served as President and Chief Operating Officer and Acting Chief Financial Officer of ImmunoGen from July 2008 to December 2008, Executive Vice President and Chief Financial Officer from 2006 to July 2008, and Senior Vice President and Chief Financial Officer from 2005 to 2006. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. from 2002 until its acquisition by Deluxe Corporation in 2004, and he was Senior Vice President and Chief Financial Officer of New England Business Services from 1998 to 2002. Before joining New England Business Services, Mr. Junius was Vice President and Chief Financial Officer of Nashua Corporation from 1996 to 1998. Mr. Junius joined Nashua Corporation in 1984 and held various financial management positions of increasing responsibility before becoming Chief Financial Officer of Nashua Corporation in 1996. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Masters in Management from Northwestern University’s Kellogg School of Management. As the former Chief Executive Officer and Chief Financial Officer of ImmunoGen, a public biotechnology company, Mr. Junius has extensive leadership, management, strategic planning and financial experience in the biotechnology field. Over the course of almost 20 years as the chief financial officer of various companies, Mr. Junius gained substantial expertise in the review and preparation of financial statements, which provides valuable perspective as the Chair of the Audit Committee. Mr. Junius’s service on other public company boards, including as audit committee chair, brings additional insight to his Board service and leadership.
As the Independent Director of Idexx Laboratories, the total compensation of Daniel Junius at Idexx Laboratories is $307,482. There are 15 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.
Daniel Junius is 67, he's been the Independent Director of Idexx Laboratories since 2014. There are 2 older and 23 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
Daniel's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers oraz Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: